July 18, 2023 – The FDA has approved a vaccine that is very effective in protecting infants from potentially fatal illness attributable to respiratory syncytial virus (RSV). Almost all children may have an RSV infection by their second birthday.
The recent preventive treatment, called Beyfortus, accommodates antibodies that reduce the danger of severe infection by as much as 75%. Protection can last as long as 5 months, concerning the length of the standard RSV season. On Monday, the FDA approved the vaccine for babies up to at least one 12 months old and in addition for toddlers as much as two years old, who're in a high-risk group.
“RSV can cause severe illness in infants and some children and results in a large number of emergency room and physician visits each year,” said John Farley, MD, MPH, director of the FDA Office of Infectious Diseases in a opinion“Today’s approval addresses the great need for products that help reduce the impact of RSV disease on children, families and the health care system.”
RSV is blamed for greater than 2 million outpatient visits, as much as 80,000 hospitalizations and as much as 300 deaths in children under 5 annually. An early surge within the virus last fall filled some pediatric wards to capability amid the so-called “triple epidemic,” when the country faced high rates of COVID-19, influenza and RSV concurrently.
The pharmaceutical company AstraZeneca announced in a Press release that Beyfortus will probably be available before the beginning of the 2023/24 RSV season. It is already approved and available in Europe and Canada. The most typical side effect in clinical trials was rash.
RSV symptoms include a runny nose, decreased appetite, cough, sneezing, fever and wheezing, in response to the CDC.
“These symptoms usually appear gradually and not all at once,” the CDC's website says concerning the virus. “In very young infants with RSV, the only symptoms may be irritability, decreased activity, and difficulty breathing.”